The Course of Ischemic Heart Disease and Metabolic Syndrome Elderly Patients
Keywords:
Ischemic heart disease, metabolic syndrome, elderly patientsAbstract
To understand how ischemic heart disease and metabolic syndrome develop and progress in elderly patients, and to explore effective ways to diagnose, manage, and treat these conditions in this age group.
189 elderly patients were involved in the study, and they were divided into two groups based on the presence or absence of metabolic syndrome (MS). The first group consisted of 125 patients with both Ischemic heart disease (IHD) and MS (the main group), while 64 patients had Ischemic heart disease (IHD) without MS (the control group). The study examined components of metabolic syndrome, including obesity, hypertension, hyperglycemia, and hyperlipidemia in all patients. Complaints were assessed, and objective indicators such as body mass index (BMI), heart murmurs, and lung wheezing were analyzed.
That stable angina was recorded in 68% of cases in the IHD + MS group, which is significantly higher than in the IHD without MS group (45%, p<0.01). The presence of MS is presumed to increase the risk of angina. In the UTI + MS group, 25% of the patients had experienced a myocardial infarction, whereas this figure was 15% in the UTI without MS group (p<0.05). This indicates that the presence of MS increases the risk of developing myocardial infarction. Chronic heart failure (CHF) was observed in 35% of cases in the IHD + MS group, which is significantly higher compared to 20% in the IHD without MS group (p<0.05). MS may contribute to CHF through increased cardiac load and inflammatory processes.
Patients in the IHD + MS group scored significantly lower in quality-of-life measures compared to the IHD without MS group. Metabolic syndrome drastically reduces the quality of life physically, mentally, and socially.
References
Grundy SM, Cleeman JI, Daniels SR, et al."Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement."Circulation. 2021; 112(17): 2735-2752.
Eckel RH, Alberti KG, Grundy SM, Zimmet PZ."The metabolic syndrome."The Lancet. 2021; 398(10307): 274-286.
Reaven GM."Insulin resistance and its consequences: Type 2 diabetes and other metabolic abnormalities."Diabetes. 2019; 68(2): 436-442.
DOI: 10.2337/db19-0101.
Zhou B, Carrillo-Larco RM, Danaei G, et al."Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2020."The Lancet. 2021; 398(10304): 957-980.
DOI: 10.1016/S0140-6736(21)01330-1
Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH."Prevalence of the metabolic syndrome and its association with cardiovascular disease among US adults."JAMA. 2019; 305(3): 256-266.
DOI: 10.1001/jama.2018.1686
Mancia G, Fagard R, Narkiewicz K, et al."ESH/ESC Guidelines for the management of arterial hypertension."Journal of Hypertension. 2020; 38(7): 1115-1181 DOI: 10.1097/HJH.0000000000002413